Biomarkers of Response for Clinical Trials

Welcome to the eighth in our series of case studies showcasing Metabolon clients’ achievements in discovery, preclinical, and clinical research.

Here, our client developed a patient-friendly way to show the efficacy of potential therapies for a severe form of liver inflammation – nonalcoholic steatohepatitis (NASH) – which has no FDA-approved treatments. This group of 22 potential blood biomarkers could replace the need for costly imaging or invasive liver biopsies in clinical trials for this disease.